Inscripta

Enabling rapid exploration of the genetic landscape

About

Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease free for research and development purposes, the company enables scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Paladin Capital Group, Mérieux Développement, NanoDimension, MLS Capital, JS Capital Management LLC, and Oak HC/FT. For more information, visit www​.inscrip​ta​.com.

  • Location: Boulder, CO
  • Paladin Initial Investment Date: February 2017

Our Co-Investor Partners

Portfolio Stats

Over 75 Companies

Paladin has invested in over 75 portfolio companies since 2001.

4 Continents

Paladin has invested in companies in North America, Australia, Europe, and South America.

Over $2 billion

Paladin was founded in 2001 and has since managed over $2B of companies and assets.